<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478620</url>
  </required_header>
  <id_info>
    <org_study_id>CanUTI2</org_study_id>
    <secondary_id>2011-000838-11</secondary_id>
    <nct_id>NCT01478620</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)</brief_title>
  <official_title>An Open-label, Non-randomized, Multicenter, Interventional Study to Investigate the Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionorica SE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionorica SE</source>
  <brief_summary>
    <textblock>
      The objective of the study is to assess safety and impact of a non-antibiotic therapy
      approach with Canephron® N in the management strategy of uncomplicated lower urinary tract
      infections (UTIs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      250 patients total 7-day treatment period with Canephron® N (2 tablets three times a day) and
      a follow-up period until Day 37. A total of three visits are planned on Day 0 (screening,
      start of study treatment), Day 7 (end of study treatment) and Day 37 (end of study visit).

      Additional visits can be performed anytime between Day 1 and Day 37 if deemed necessary by
      the investigator. In case the patients experience consistent or worsening of symptoms they
      may be offered antibiotic therapy at the discretion of the investigator at any time. In this
      case Canephron® N intake will be stopped.

      At least 50% of the patients, i.e. 125 subjects, should have received a 7-day treatment with
      Canephron® N. If less subjects are available recruitment of subjects will be continued until
      the required number of 125 subjects is reached.

      Due to withdrawal of study in Russia total study population was reduced to 125 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Drug Reactions During 7-day Treatment of uUTI Symptoms With Canephron® N</measure>
    <time_frame>During active treatment period (day 1 until day 7)</time_frame>
    <description>No study drug related adverse drug reactions were registered.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Drug Reactions During the 7-day Treatment of uUTI Symptoms With Canephron® N in the Subgroup of Patients Who Take Canephron® N for at Least 7 Days</measure>
    <time_frame>During active treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With no Symptoms Worse Than Mild on Day 7 (i.e. Responders)</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of uUTI Symptoms on Day 7</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of uUTI Symptoms on Day 37</measure>
    <time_frame>Day 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of uUTI Symptoms</measure>
    <time_frame>During active treatment and follow up period (Day 0 - Day 37)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Require Antibiotic Treatment Until Day 7</measure>
    <time_frame>During active treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Early Recurrence [Days] After Clearance of uUTI Symptoms</measure>
    <time_frame>During active treatment and follow up period (Day 0 - Day 37)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Early Recurrence [Days] After Clearance of uUTI Symptoms</measure>
    <time_frame>During active treatment and follow up period (Day 0 - Day 37)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Canephron® N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canephron® N</intervention_name>
    <description>3x 2 coated tablets/day for 7 days p.o.</description>
    <arm_group_label>Canephron® N</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Female outpatients aged 18-65 years (both inclusive).

          -  Patients suffering of symptoms of uncomplicated lower urinary infection at screening.
             Patients must have a total sum score of at least six for the symptoms dysuria,
             frequency and urgency.

          -  Development of symptoms within a maximum of 6 days before screening.

          -  Willing to refrain from consuming prohibited concomitant medications and products.

          -  Non-lactating female patients, who are surgically sterile (have had a documented
             bilateral oophorectomy and/or hysterectomy) or postmenopausal (cessation of menses for
             more than 1 year), or patients of childbearing potential with a negative pregnancy
             test at screening willing to use effective contraception methods (intrauterine device
             [IUD], hormonal contraceptives) during the study.

        Main Exclusion Criteria:

          -  Any signs evoking complicated UTI, pyelonephritis and/or concomitant vulvo-vaginitis

          -  Any conditions that may lead to complicated infections (that is, renal diseases,
             urinary tract abnormalities or past urinary surgery, urine catheterization, etc).

          -  Chronic infection of the urinary tract requiring an intravenous pyelogram (IVP),
             ultrasound or cystoscopy.

          -  Current signs or symptoms of severe, progressive or uncontrolled life-threatening
             systemic disease i.e. renal, hepatic, haematological, gastrointestinal, endocrine,
             pulmonary, cardiac, neurological, or cerebral disease.

          -  Other acute infection (except UTI) requiring antibiotic treatment.

          -  Patients receiving treatment for presumed or proven urinary tract infection within 4
             weeks prior to study entry.

          -  Antibiotic, immunosuppressive or immunostimulant (incl. vaccines) therapy within 4
             weeks prior to study entry.

          -  Patients with known history of anatomical genitourinary (GU) anomalies or GU surgery
             within 6 months prior to study entry.

          -  Patients with known clinically significant abnormalities in screening physical
             examination, laboratory tests or vital signs.

          -  Peptic ulcers and hypersensitivity and/or idiosyncrasy to centaury herb, lovage root,
             rosemary leaves or one of the other ingredients of the investigational medicinal
             product.

          -  Rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or
             sucrase-isomaltase insufficiency, galactose intolerance or lactase deficiency.

          -  Patients with a history of severe drug allergy or hypersensitivity.

          -  Known Human Immunodeficiency Virus (HIV)-seropositivity.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuriy Gennadyevich Alyayev, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Moscow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>9 Sites</name>
      <address>
        <city>Ukraine</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <results_first_submitted>August 27, 2014</results_first_submitted>
  <results_first_submitted_qc>October 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 13, 2014</results_first_posted>
  <last_update_submitted>October 10, 2014</last_update_submitted>
  <last_update_submitted_qc>October 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Canephron® N</title>
          <description>3x 2 coated tablets/day for 7 days p.o.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Canephron® N</title>
          <description>3x 2 coated tablets/day for 7 days p.o.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>female participants</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>uncomplicated urinary tract infection symptom score</title>
          <description>The severity of uUTI symptoms was assessed daily by the patient as well as by the investigator at each study visit. The following uUTI symptoms were rated on a 5-point scale: dysuria, frequency, urgency, acute development of incontinence or worsening of incontinence, nocturia, pain or discomfort in lower abdomen or pelvic areas and increased body temperature.
The assessment of the symptoms ranged from 0 (absent or &lt;/= 37°C) to 4 (very severe or &gt;/= 40°C).
At baseline the total sum score (sum of subscales) of the symptoms dysuria, frequency and urgency had to be at least &gt;/= 6.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Drug Reactions During 7-day Treatment of uUTI Symptoms With Canephron® N</title>
        <description>No study drug related adverse drug reactions were registered.</description>
        <time_frame>During active treatment period (day 1 until day 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Canephron® N</title>
            <description>3x 2 coated tablets/day for 7 days p.o.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Drug Reactions During 7-day Treatment of uUTI Symptoms With Canephron® N</title>
          <description>No study drug related adverse drug reactions were registered.</description>
          <units>Adverse Drug Reactions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Drug Reactions During the 7-day Treatment of uUTI Symptoms With Canephron® N in the Subgroup of Patients Who Take Canephron® N for at Least 7 Days</title>
        <time_frame>During active treatment period</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With no Symptoms Worse Than Mild on Day 7 (i.e. Responders)</title>
        <time_frame>Day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of uUTI Symptoms on Day 7</title>
        <time_frame>Day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of uUTI Symptoms on Day 37</title>
        <time_frame>Day 37</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of uUTI Symptoms</title>
        <time_frame>During active treatment and follow up period (Day 0 - Day 37)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Require Antibiotic Treatment Until Day 7</title>
        <time_frame>During active treatment period</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Early Recurrence [Days] After Clearance of uUTI Symptoms</title>
        <time_frame>During active treatment and follow up period (Day 0 - Day 37)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Early Recurrence [Days] After Clearance of uUTI Symptoms</title>
        <time_frame>During active treatment and follow up period (Day 0 - Day 37)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Canephron® N</title>
          <description>3x 2 coated tablets/day for 7 days p.o.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Each Party acknowledges that it shall not publish any results of the trial,without the prior written authorization of the other Party. If SPONSOR (S.) requests INVESTIGATOR (I.)to publish any results obtained from the study, I. shall prepare and accomplish such publication at the expense of S. after review by S. and subject to written approval of the S. prior to publication. I. must be mentioned as co-author in any kind of publication resulting from such a request by S. to I. to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ivanov, Dmitry</name_or_title>
      <organization>&quot;Kiev regional City Hospital&quot;</organization>
      <phone>+38 (039) 247 12 36</phone>
      <email>ivanovdd@i.kiev.ua</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

